CN113577303B - 三分枝rgd修饰的脑胶质瘤靶向脂质材料的制备和应用 - Google Patents
三分枝rgd修饰的脑胶质瘤靶向脂质材料的制备和应用 Download PDFInfo
- Publication number
- CN113577303B CN113577303B CN202110757554.6A CN202110757554A CN113577303B CN 113577303 B CN113577303 B CN 113577303B CN 202110757554 A CN202110757554 A CN 202110757554A CN 113577303 B CN113577303 B CN 113577303B
- Authority
- CN
- China
- Prior art keywords
- glioma
- lipid material
- liposome
- rgd
- brain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000002632 lipids Chemical class 0.000 title claims abstract description 38
- 239000000463 material Substances 0.000 title claims abstract description 33
- 201000007983 brain glioma Diseases 0.000 title claims abstract description 25
- 230000008685 targeting Effects 0.000 title claims abstract description 23
- 238000002360 preparation method Methods 0.000 title claims description 35
- 239000002502 liposome Substances 0.000 claims abstract description 87
- 229930012538 Paclitaxel Natural products 0.000 claims abstract description 33
- 229960001592 paclitaxel Drugs 0.000 claims abstract description 33
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims abstract description 33
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 29
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 claims abstract description 28
- 206010018338 Glioma Diseases 0.000 claims abstract description 18
- 208000032612 Glial tumor Diseases 0.000 claims abstract description 15
- 235000012000 cholesterol Nutrition 0.000 claims abstract description 14
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 claims abstract description 5
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 5
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 3
- 239000003814 drug Substances 0.000 claims description 30
- 229940079593 drug Drugs 0.000 claims description 19
- 239000013543 active substance Substances 0.000 claims description 12
- 239000002245 particle Substances 0.000 claims description 10
- 150000003904 phospholipids Chemical class 0.000 claims description 9
- 238000005538 encapsulation Methods 0.000 claims description 7
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 6
- 235000010445 lecithin Nutrition 0.000 claims description 6
- 239000000787 lecithin Substances 0.000 claims description 6
- 229940067606 lecithin Drugs 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 238000006703 hydration reaction Methods 0.000 claims description 5
- 239000008363 phosphate buffer Substances 0.000 claims description 5
- 230000036571 hydration Effects 0.000 claims description 4
- 239000012528 membrane Substances 0.000 claims description 4
- 239000004475 Arginine Substances 0.000 claims description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 3
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 claims description 3
- 239000004471 Glycine Substances 0.000 claims description 2
- 235000003704 aspartic acid Nutrition 0.000 claims description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 125000006239 protecting group Chemical group 0.000 claims 3
- PBLZLIFKVPJDCO-UHFFFAOYSA-N 12-aminododecanoic acid Chemical compound NCCCCCCCCCCCC(O)=O PBLZLIFKVPJDCO-UHFFFAOYSA-N 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical class OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 claims 1
- 239000002994 raw material Substances 0.000 claims 1
- 239000007858 starting material Substances 0.000 claims 1
- 230000002194 synthesizing effect Effects 0.000 claims 1
- 239000010409 thin film Substances 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 9
- 210000002889 endothelial cell Anatomy 0.000 abstract description 5
- 229940126585 therapeutic drug Drugs 0.000 abstract description 5
- 208000003174 Brain Neoplasms Diseases 0.000 abstract description 4
- 210000004781 brain capillary Anatomy 0.000 abstract description 4
- 210000004556 brain Anatomy 0.000 abstract description 3
- 239000002552 dosage form Substances 0.000 abstract description 2
- 239000000693 micelle Substances 0.000 abstract description 2
- 239000002105 nanoparticle Substances 0.000 abstract description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 87
- 238000006243 chemical reaction Methods 0.000 description 50
- 210000004027 cell Anatomy 0.000 description 42
- 239000000243 solution Substances 0.000 description 41
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 36
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 19
- 239000003446 ligand Substances 0.000 description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 239000012044 organic layer Substances 0.000 description 18
- 102000005962 receptors Human genes 0.000 description 17
- 108020003175 receptors Proteins 0.000 description 17
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
- 230000004913 activation Effects 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- 238000005119 centrifugation Methods 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 206010018910 Haemolysis Diseases 0.000 description 7
- 230000008588 hemolysis Effects 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 238000004440 column chromatography Methods 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 238000009987 spinning Methods 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 102000006495 integrins Human genes 0.000 description 5
- 108010044426 integrins Proteins 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 238000002390 rotary evaporation Methods 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000003208 petroleum Substances 0.000 description 4
- 238000001959 radiotherapy Methods 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 229910002091 carbon monoxide Inorganic materials 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000002539 nanocarrier Substances 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000008347 soybean phospholipid Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002834 transmittance Methods 0.000 description 3
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 2
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 2
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 2
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 2
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 2
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 2
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 2
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 2
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 2
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229940126657 Compound 17 Drugs 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 244000061458 Solanum melongena Species 0.000 description 2
- 235000002597 Solanum melongena Nutrition 0.000 description 2
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- -1 but not limited to Chemical class 0.000 description 2
- 229940125773 compound 10 Drugs 0.000 description 2
- 229940126543 compound 14 Drugs 0.000 description 2
- 229940125758 compound 15 Drugs 0.000 description 2
- 229940126142 compound 16 Drugs 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940125810 compound 20 Drugs 0.000 description 2
- 229940126086 compound 21 Drugs 0.000 description 2
- 229940126208 compound 22 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000013557 residual solvent Substances 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 229960004964 temozolomide Drugs 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- 238000009210 therapy by ultrasound Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 239000012624 DNA alkylating agent Substances 0.000 description 1
- 230000008265 DNA repair mechanism Effects 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 244000178870 Lavandula angustifolia Species 0.000 description 1
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 102000019997 adhesion receptor Human genes 0.000 description 1
- 108010013985 adhesion receptor Proteins 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 229960004104 amiloride hydrochloride Drugs 0.000 description 1
- LTKVFMLMEYCWMK-UHFFFAOYSA-N amiloride hydrochloride dihydrate Chemical compound [H+].O.O.[Cl-].NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N LTKVFMLMEYCWMK-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000007428 craniotomy Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- JRBPAEWTRLWTQC-UHFFFAOYSA-N dodecylamine Chemical compound CCCCCCCCCCCCN JRBPAEWTRLWTQC-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002121 endocytic effect Effects 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000004896 high resolution mass spectrometry Methods 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 239000001102 lavandula vera Substances 0.000 description 1
- 235000018219 lavender Nutrition 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 238000004848 nephelometry Methods 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- ZPIRTVJRHUMMOI-UHFFFAOYSA-N octoxybenzene Chemical compound CCCCCCCCOC1=CC=CC=C1 ZPIRTVJRHUMMOI-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 239000003504 photosensitizing agent Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 150000004579 taxol derivatives Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了一类三分枝RGD修饰的脑胶质瘤靶向脂质材料,用于实现脑胶质瘤治疗药物的靶向递送。所述的新型脂质材料通过分枝骨架,一端连接聚乙二醇延伸的胆固醇,另外一端连接三分子具有脑胶质瘤靶向功能的RGD肽,可利用该新型脂质材料与脑毛细血管内皮细胞和脑胶质瘤细胞表面高度表达的整合素受体αvβ3之间的亲和力,实现对脑胶质瘤的精准靶向作用,提高治疗药物到达脑肿瘤的有效浓度。该新型脂质脂质材料可用于脂质体、纳米粒、胶束等在内的不同剂型,所制成的载紫杉醇脂质体具有明显的脑靶向性和肿瘤靶向性,拥有广阔的应用前景。
Description
技术领域
本发明涉及一类新型脂质材料及其在药物传递系统中的应用,具有脑胶质瘤治疗药物靶向传递的功能,本发明包括该材料的制备和表征,及其作为药物载体在药物传递中的应用,属于医药技术和化学合成领域。
背景技术
脑胶质瘤作为中枢神经系统(Central Nervous System, CNS)最常见的侵袭性恶性肿瘤,占中枢神经系统恶性肿瘤的81%,是预后最差和最具破坏性的癌症之一,具有恶性程度高、致死率高和易复发等特点。脑胶质瘤在各个年龄段内均有发生,在45岁以上的人群中发病率更高,且男性比女性更易罹患该疾病。脑胶质瘤具有高侵袭性、难治愈和易复发等特点,通常导致高致死率和对神经系统的永久伤害,给患者带来极大痛苦。
目前临床上针对脑胶质瘤的治疗方法主要包括:1)外科手术;2)放射疗法;3)化学治疗;4)靶向治疗。一般来说,在脑胶质瘤诊断后立即进行手术切除可有效控制肿瘤的进展,明显提高患者的预后水平。而对于恶性程度较高的弥漫性脑胶质瘤,临床上常通过清醒开颅术以及术中电刺激图引导方式进行辅助,但即便如此,侵入正常脑组织的肿瘤细胞仍难以完全清除。针对这一类型的肿瘤,术后常须进行多疗程的放疗和化疗以进一步巩固手术的治疗效果,尽可能完全地清除肿瘤细胞,降低癌症复发的可能。另外,目前批准用于治疗脑胶质瘤的一线药物主要包括三种DNA烷化剂(替莫唑胺、洛莫司汀、卡莫司汀)和一种拮抗血管内皮生长因子(Vascular endothelial growth factor, VEGF)的靶向制剂(贝伐单抗)。研究表明替莫唑胺与放疗相结合与单独放疗相比可显著延长脑胶质瘤患者的中位生存期。然而这些治疗药物仍存在许多限制,由于血脑屏障、肿瘤异质性、药物外排泵和DNA修复机制等因素,使它们无法在脑内肿瘤部位达到理想的治疗效果,常引发治疗耐药性和全身性的毒副作用。且目前用于治疗脑胶质瘤的药物主要为全身性药物,缺乏针对脑胶质瘤细胞的靶向制剂。
与常规制剂相比,纳米载体可有助于药物跨血脑屏障输送,使其包载的药物在脑肿瘤部位达到有效蓄积,并且将药物包载于纳米载体内可帮助药物抵抗体内酶的清除,延长其在体内的循环时间,在纳米载体的帮助下到达特定部位发挥作用,从而提高药物的疗效和安全性。脂质体是目前研究最多的一种纳米载药系统,具有易制备、低毒、生物相容性高、高负载能力、可控的释放动力学等优点,已被广泛用于全身性治疗药物,具有极高的研究价值。除此之外,在脂质体表面修饰特定的大分子配体后还可进一步增强其对脑肿瘤的主动靶向能力。目前常用于修饰在脂质体表面的配体有肽、抗体和一些小分子配体(如叶酸)等。
整合素受体作为一类细胞粘附受体,在细胞-细胞间和细胞-基质间的信号传导中起关键调节作用,直接影响肿瘤细胞的增殖、存活和迁移。在整合素受体所有亚型中,αvβ3亚型最受关注,αvβ3受体在脑胶质瘤细胞和肿瘤新生血管内皮细胞中均高度表达,并且在脑毛细血管内皮细胞表面也有较高程度的表达,但在正常组织早已存在的内皮上不表达,该特异性使αvβ3受体成为重要的肿瘤标志物,并成为医学成像模式用于检测肿瘤组织和肿瘤血管生成的靶标。RGD是精氨酸(Arg)、甘氨酸(Gly)和天冬氨酸(Asp)形成的三肽,多种亚型的整合素受体均能识别相同的核心氨基酸序列Arg-Gly-Asp (RGD),因此RGD是整合素受体最重要的底物分子,并与αvβ3受体有高度的亲和力。由于脑毛细血管内皮细胞和脑胶质瘤细胞表面高表达αvβ3受体,因此,我们设想将RGD修饰于脂质体表面,亦可实现对脑胶质瘤的靶向。
除了配体与受体的亲和力外,配体数量也是影响脂质体靶向能力的重要因素。研究表明,脂质体表面的配体密度与体外细胞摄取呈正相关,提高靶向分子的密度,能够显著提升脂质体的靶向能力。另外,整合素受体存在受体簇聚现象,整合素受体被激活后会在周围募集更多的受体,从而导致受体之间的距离变小。在这种情况下,采用多价分枝配体的形式将能更好响应受体簇聚现象,从而增强脂质体的靶向能力。
发明内容
本研究的目的是合成一种具有多价分枝结构的脂质材料,并将其用于脂质体的制备。利用RGD肽与脑毛细血管内皮细胞和脑胶质瘤细胞表面高表达的αvβ3受体的高度亲和力,通过多价分枝配体的形式增加RGD分子在脂质体表面的密度,从而进一步提高脂质材料对脑胶质瘤的靶向性。另外,由于受体簇聚现象的存在,分枝配体中RGD残基间的空间距离对于配体与受体的结合也有较大影响。因此在本发明中,采用12-氨基十二烷对RGD部分进行延伸,从而使分枝配体拥有最适宜与受体结合的构象。
将这种三分枝RGD修饰的脂质材料应用于具体的制剂,具有以下优点:经多分枝RGD修饰的脂质体可通过EPR效应和对αvβ3受体的特异性识别作用,实现对脑胶质瘤的被动靶向和主动靶向作用,从而提高包载药物在脑肿瘤组织的蓄积浓度,提高药物的治疗特异性,显著改善用药安全性,减少正常组织的毒副作用;使用生物相容性的载体材料包载药物,可以减少免疫反应以及网状内皮系统的吞噬;脂质材料与所包载的药物整体进入肿瘤细胞后再释放药物,可以减少药物与外排蛋白的作用,从而降低耐药性;该脂质材料可结合多种药物对脑胶质瘤实施联合给药。因此,我们设计了如通式(I)所示的一类脂质材料,该脂质材料的胆固醇部分嵌入到脂质体磷脂双分子层中,具有脑胶质瘤靶向的RGD部分暴露在脂质体的表面,从而使脂质体具有脑靶向和肿瘤靶向功能。这种脂质材料可用于脂质体、纳米粒、胶束等在内的不同剂型,具有很大的应用前景。
本发明提供通式(I)所示结构的化合物或其药学上可接受的盐或水合物:
其中,所用PEG的分子量等于但并不仅限于200、400、600、800、1000、1500、2000、4000等。
通式(I)所示化合物的具体制备方法如下所示:
本发明所述的新型脂质材料可以作为配体用于制备脑胶质瘤靶向脂质体。
所述脂质体其特征在于包含磷脂、胆固醇、通式I(3RGD-Chol)及活性剂。
所述脂质体主要由膜材与活性剂组成,其膜材为磷脂双分子层,由卵磷脂,胆固醇以及脂质体配体组成,其中,各组分配比关系如下:胆固醇和磷脂的摩尔比为1~2:1~10,脂质体配体的摩尔含量为胆固醇和磷脂的总摩尔数的1~25%。本发明所述的活性剂优选治疗剂或显影剂,如本领域所知的,活性剂的剂量可以依据包含在载体中的活性剂来调整,其中按重量百分数计算,活性剂占总脂质的0.1%~50%。
所述的脂质体中的磷脂包括所有类型的磷脂,包括但不限于大豆磷脂、卵磷脂、磷脂酰乙醇胺、磷脂酰丝氨酸、磷脂酰肌醇、磷脂酰甘油、二磷脂酰甘油;优选卵磷脂。
所述的脂质体中的活性剂可以是抗肿瘤药物,包括但不限于烷化剂、抗代谢物、抗肿瘤抗生素、蒽环类抗生素、植物生物碱、紫杉醇衍生物、拓朴异构酶抑制剂、单克隆抗体、光敏剂、激酶抑制剂和含铂化合物。
本发明所述的脑胶质瘤靶向脂质体的制备方法,包括以下步骤:
(一)称取磷脂、胆固醇、紫杉醇于茄型烧瓶中,用适量溶剂溶解,加入相应比例的脂质体配体(空白脂质体不加),于20-40 °C恒温水浴旋转蒸发除去有机溶剂;
(二)再将茄型瓶置于真空干燥器中真空干燥过夜除去残余溶剂;
(三)向茄型瓶中加入磷酸盐缓冲液或硫酸铵溶液等水化液,用20 °C恒温空气浴摇床水化约0.5-2小时后,冰水浴探头超声,用挤压过膜或超声等方法将脂质体粒径控制在160 nm以下。
优选的步骤(一)中的紫杉醇:脂质材料比为1:30。
优选的步骤(一)中的溶剂为氯仿,脂质摩尔比1:2(胆固醇:大豆磷脂)。
优选的步骤(三)中的水化液为pH 7.4的0.01 M磷酸盐缓冲液(PBS)。
本发明通过以下技术方案实现上述目的:
具体实施方式
以下实施例旨在说明本发明而不是对本发明的进一步限定。下面参照实施例进一步详细阐述本发明,但本发明并不限于这些实施例以及使用的制备方法。而且,本领域技术人员根据本发明的描述可以对本发明进行等同替换、组合、改良或修饰,但这些都将包括在本发明的范围内。
所述的新型脂质材料具体由以下步骤制备:
实施例1化合物2的制备
将化合物1(4.00 g, 18.58 mmol)溶于水/四氢呋喃(30 mL + 30 mL)混合溶液中,加入氢氧化钠(1.50 g, 37.16 mmol)。然后向反应液中缓慢滴加二碳酸二叔丁酯(4.88g, 22.30 mmol)的四氢呋喃溶液(20 mL),滴毕,室温搅拌5 h。TLC监测反应完全后,旋除四氢呋喃。将残留物中溶于20 mL乙酸乙酯,冰浴下用3N HCl水溶液调pH至3左右。随后分离有机层,水层用乙酸乙酯萃取。合并有机层,浓缩得5.50 g白色固体。收率为93.86%。M.p.83.3-83.6 ℃(文献M.p. 83.5-84.5 ℃)。1H NMR (400 MHz, DMSO-d 6 ): δ 11.94 (s,1H), 6.73 (s, 1H), 2.88 (q, J = 6.6 Hz, 2H), 2.18 (t, J = 7.3 Hz, 2H), 1.47(s, 2H), 1.36 (s, 11H), 1.23 (s, 14H)。
实施例2
化合物5的制备
将化合物3(10.00 g, 57.08 mmol)溶于50 mL四氢呋喃,溶清后将反应液移至-10℃。依次缓慢滴加N-甲基吗啉(NMM, 6.29 mL, 57.08 mmol)和氯甲酸异丁酯(IBCF, 7.22mL, 57.08 mL),滴毕,于-10 ℃下活化30 min。将化合物4(2.81 g, 57.08 mmol)溶于50mL四氢呋喃,加入N-甲基吗啉(6.29 mL, 57.08 mmol)搅拌直至溶清。待上述活化液反应30min后,将该反应液于-10 ℃下缓慢滴入活化液中,滴加完毕后将反应体系移至室温,搅拌过夜。TLC监测反应完全后,减压旋除溶剂。将残留物溶于二氯甲烷,依次用1N HCl水溶液、饱和NaHCO3溶液、饱和食盐水洗涤。收集有机层,浓缩得到26.00 g黄棕色油状产品,收率为96.80%。1H NMR (400 MHz, CDCl3): δ 7.38–7.24 (m, 10H), 5.14 (s, 2H), 5.05 (d, J= 2.9 Hz, 2H), 4.93–4.85 (m, 1H), 3.83–3.75 (m, 2H), 3.11–3.05 (m, 1H), 2.93–2.87 (m, 1H), 1.45 (s, 9H)。
实施例3
化合物6的制备
将化合物5(25.81 g, 54.86 mmol)溶于100 mL二氯甲烷中,加入30 mL三氟乙酸(CF3COOH),将反应液置于30 ℃搅拌8 h。TLC监测反应完全后,减压旋除二氯甲烷和过量的三氟乙酸。残留物重新用100 mL二氯甲烷溶解,用饱和Na2CO3溶液调pH至8左右。分离有机层,水层用二氯甲烷萃取。合并有机层,用饱和食盐水洗涤。收集有机相,浓缩得到19.50 g黄棕色半固体,收率为95.96%。产品直接进行下一步反应。
实施例4
化合物8的制备
将化合物7(12.85 g, 40.26 mmol)溶于40 mL二氯甲烷中,溶清后将反应液移至-10 ℃。依次缓慢滴加N-甲基吗啉(4.43 mL, 40.26 mmol)和氯甲酸异丁酯(5.09 mL,40.26 mmol),滴毕,于-10 ℃下继续活化30 min。将化合物6(19.50 g, 40.26 mmol)溶于50 mL二氯甲烷中,加入N-甲基吗啉(4.43 mL, 40.26 mmol)搅拌直至溶清。待上述活化液反应30 min后,将该反应液于-10 ℃下缓慢滴加入活化液中,滴加完毕后将反应体系移至室温,搅拌过夜。TLC监测反应完全后,向反应液中补加适量二氯甲烷,依次用1N HCl水溶液、饱和食盐水洗涤。收集有机层并将其浓缩,残留物经柱层析(石油醚:乙酸乙酯=2:1)得到18.82 g淡黄棕色半固体,收率为69.68%。1H NMR (400 MHz, CDCl3): δ 8.41 (br, 1H),7.75 (s, 1H), 7.34–7.22 (m, 10H), 5.08 (d, J = 5.3 Hz, 2H), 5.04 (s, 2H),4.91 (s, 1H), 4.47 (s, 1H), 4.18 (s, 1H), 3.86–3.75 (m, 1H), 3.25 (s, 1H),3.15–3.00 (m, 2H), 2.94–2.88 (m, 1H), 1.70 (s, 4H), 1.39 (s, 9H)。
实施例5
化合物9的制备
将化合物8(10.00 g, 14.90 mmol)溶于50 mL二氯甲烷中,加入20 mL三氟乙酸,将反应液置于30 ℃搅拌5 h。TLC监测反应完全后,减压旋除二氯甲烷和过量的三氟乙酸。残留物重新用50 mL二氯甲烷溶解,用饱和Na2CO3溶液调pH至8左右。分离有机层,水层用二氯甲烷萃取。合并有机层,用饱和食盐水洗涤。收集有机相并将其浓缩,得到8.37 g黄棕色半固体,收率为95.96%。产品直接进行下一步反应。
实施例6
化合物10的制备
将化合物2(3.53 g, 11.17 mmol)溶于20 mL二氯甲烷中,溶清后将反应液移至-10 ℃。依次缓慢滴加N-甲基吗啉(1.57 mL, 11.17 mmol)和氯甲酸异丁酯(1.42 mL,11.17 mmol),滴毕,于-10 ℃下继续活化30 min。将化合物9(6.38 g, 11.17 mmol)溶于30mL二氯甲烷中,加入N-甲基吗啉(1.57 mL, 11.17 mmol)搅拌直至溶清。待上述活化液反应30 min后,将该反应液于-10 ℃下缓慢滴加入活化液中,滴加完毕后将反应液移至室温,搅拌过夜。TLC监测反应完全后,向反应液中补加适量二氯甲烷,依次用1N HCl水溶液、饱和食盐水洗涤。收集有机层并将其浓缩,残留物经柱层析(二氯甲烷:甲醇=60:1)得到8.36 g淡黄棕色油状产品,收率为86.24%。1H NMR (400 MHz, DMSO-d 6 ): δ 8.51 (br, 1H), 8.37(d, J = 7.8 Hz, 1H), 8.24 (s, 1H), 8.02 (d, J = 7.0 Hz, 1H), 7.36–7.30 (m,10H), 5.09 (s, 2H), 5.07(s, 2H), 4.81–4.75 (m, 1H), 4.24–4.16 (m, 1H), 3.78–3.68 (m, 2H), 3.14 (s, 2H), 2.92–2.80 (m, 4H), 2.10 (s, 2H), 1.57–1.43 (m,6H), 1.36 (s, 9H), 1.20 (s, 16H)。
实施例7
化合物11的制备
将化合物10(1.50 g, 1.73 mmol)溶于50 mL二氯甲烷中,加入5 mL三氟乙酸,将反应液置于30 ℃搅拌5 h。TLC监测反应完全后,将反应液旋干。残留物重新溶于30 mL二氯甲烷,用饱和Na2CO3溶液调pH至8左右。分离有机层,水层用二氯甲烷萃取,合并有机层,用饱和食盐水洗涤。收集有机相并将其浓缩,得到1.31 g黄棕色半固体,收率为98.62%。产品直接进行下一步反应。
实施例8
化合物13的制备
将胆固醇12(32.00 g, 82.76 mmol)溶于80 mL无水吡啶中,于0 ℃下缓慢滴加对甲苯磺酰氯(25.24 g, 132.42 mmol)的吡啶溶液(45 mL),滴毕,移至55 ℃搅拌过夜。TLC监测反应完全后,旋除吡啶。将残留物溶于乙酸乙酯,依次用1N HCl水溶液和饱和食盐水洗涤,收集有机层并将其浓缩,得28.46 g米白色固体,收率为59.57%。产品直接进行下一步反应。m.p. 130.5-131.3 ℃(文献m.p. 130-132 ℃)。
实施例9
化合物14的制备
将化合物13(18.28 g, 33.80 mmol)溶于40 mL二氧六环,将反应液置于90 ℃油浴中搅拌。待化合物12完全溶清后,加入三甘醇(22.67 mL, 169.01 mmol),升温至120 ℃回流反应8 h。TLC监测反应完全后,旋除溶剂。残留物用乙酸乙酯溶解,并用饱和食盐水洗涤。收集有机层并将其浓缩,残留物经硅胶柱层析分离纯化(石油醚:乙酸乙酯=5:1),得到9.87 g淡黄棕色半固体,收率为56.30%。1H NMR (600 MHz, CDCl3): δ 5.34 (s, 1H),3.75–3.71 (m, 2H), 3.70–3.66 (m, 4H), 3.64 (s, 4H), 3.63–3.61 (m, 2H), 3.21–3.15 (m, 1H), 2.38–2.33 (m, 2H), 2.24–2.19 (m, 1H), 2.02–1.94 (m, 2H), 1.92–1.80 (m, 3H), 1.60–1.39 (m, 8H), 1.38–1.31 (m, 3H), 1.28–1.23 (m, 1H), 1.18–1.01 (m, 8H), 0.99 (s, 3H), 0.91 (d, J = 6.5 Hz, 3H), 0.86 (dd, J = 6.5, 2.6Hz, 6H), 0.67 (s, 3H)。
实施例10
化合物15的制备
氩气环境下,将化合物14(2.92 g, 5.63 mmol)溶于20 mL二氯甲烷中,加入三乙胺(Et3N, 3.91 mL, 28.15 mmol)。将反应液置于冰浴中,缓慢滴加对甲苯磺酰氯(TsCl,3.22 g, 16.89 mmol)的二氯甲烷(10 mL)溶液,滴毕,将反应液移至室温搅拌12 h。TLC监测反应完全后,向反应液中加入适量二氯甲烷稀释,依次用1N HCl水溶液和饱和食盐水洗涤。收集有机层并将其浓缩,残留物经柱层析纯化(石油醚:乙酸乙酯=15:1),得到2.8 g黄棕色油状产品,收率为73.96%。1H NMR (400 MHz, CDCl3): δ 7.78 (d, J = 7.7 Hz, 2H),7.48 (d, J = 7.7 Hz, 2H), 5.30 (s, 1H), 3.58 (s, 2H), 3.53 (s, 8H), 3.48 (s,2H), 3.10 (s, 1H), 2.42 (s, 3H), 1.95–1.88 (m, 2H), 1.86–1.73 (m, 4H), 1.56–1.44 (m, 5H), 1.35–1.29 (m, 5H), 1.26–1.20 (m, 6H), 1.15–1.04 (m, 6H), 0.93(s, 3H), 0.89 (d, J = 6.0 Hz, 3H), 0.84 (d, J = 6.0 Hz, 6H), 0.65 (s, 3H)。
实施例11
化合物16的制备
将化合物15(2.80 g, 4.16 mmol)溶于干燥N, N-二甲基甲酰胺(DMF, 25 mL)中,缓慢加入叠氮钠(NaN3, 0.54 g, 8.33 mmol),将反应液移至110 ℃反应16 h。TLC监测反应完全后,减压旋除溶剂。加入适量乙酸乙酯稀释,用纯水洗涤。收集有机层并将其浓缩,得到2.23 g黄棕色油状产品,收率为98.86%。产品直接进行下一步反应。
实施例12
化合物17的制备
将化合物16(2.23 g, 4.10 mmol)溶于30 mL四氢呋喃中,加入三苯基膦(PPh3,1.61 g, 6.15 mmol)和纯水(1.48 mL, 82 mmol),将反应液移入50 ℃反应过夜。TLC监测反应完全后,旋除溶剂。残留物经柱层析纯化(二氯甲烷: 甲醇=30:1),得到1.76 g黄棕色油状产品,收率为82.93%。1H NMR (400 MHz, CDCl3): δ 5.34 (s, 1H), 3.68–3.61 (m,8H), 3.54 (t, J = 5.1 Hz, 2H), 3.21–3.14 (m, 1H), 2.89 (t, J = 4.9 Hz, 2H),2.38–2.33 (m, 1H), 2.22–2.16 (m, 1H), 2.03–1.76 (m, 6H), 1.56–1.42 (m, 7H),1.36–1.24 (m, 6H), 1.16–1.03 (m, 7H), 0.99 (s, 3H), 0.91 (d, J = 6.4 Hz, 3H),0.86 (d, J = 6.4 Hz, 6H), 0.67 (s, 3H)。
实施例13
化合物19的制备
氩气环境下,向化合物18(2.00 g, 14.69 mmol)加入丙烯腈(4.84 mL, 73.45mmol),将反应液移入冰浴中,搅拌下缓慢加入40% KOH(400 μL),10分钟后将反应液移至室温反应过夜。TLC监测反应完全后,旋除丙烯腈。残留物用乙酸乙酯溶解,依次用1N HCl溶液和饱和食盐水洗涤。收集有机层并将其浓缩,残留物经柱层析纯化(石油醚:乙酸乙酯=1:1),得到4.50 g无色油状产品,收率为87.92%。1H NMR (400 MHz, CDCl3): δ 3.66 (t, J =5.9 Hz, 8H), 3.49 (s, 8H), 2.60 (t, J = 5.9 Hz, 8H)。
实施例14
化合物20的制备
氩气环境下,将化合物19(4.50 g, 12.92 mmol)溶于15 mL浓盐酸,将反应液移入80 ℃回流反应3 h。TLC监测反应完全后,将反应液置于冰浴中迅速降温,滤除产生的白色沉淀,用丙酮洗涤。浓缩滤液,残留物用30 mL丙酮溶解,再次滤除产生的白色沉淀,反复操作直至不再产生白色不溶物。将溶液旋干,残留物溶于15 mL乙腈中,置于-20 ℃冰箱过夜重结晶,得到3.20 g白色晶体,收率为58.39%。M.p. 98.6-100.4 ℃(文献M.p. 99-101℃)。1H NMR (400 MHz, DMSO-d6): δ 12.12 (s, 4H), 3.52 (t, J = 6.2 Hz, 8H), 3.24(s, 8H), 2.41 (t, J = 6.2 Hz, 8H)。
实施例15
化合物21的制备
氩气环境下,将化合物20(1.22 g, 2.88 mmol)溶于30 mL二氯甲烷中,于冰浴下依次加入N, N-二异丙基乙胺(243 μL, 1.44 mmol)、HATU(411 mg, 1.08 mmol)、1-羟基苯并三唑(118 mg, 0.86 mmol),将反应液继续置于0 ℃活化30 min。将化合物17(375 mg,0.72 mmol)溶于10 mL二氯甲烷中,待上述活化液反应30 min后,将该反应液滴加入活化液中,室温反应过夜。TLC监测反应完全后,减压旋除溶剂。残留物重新用乙酸乙酯溶解,用1NHCl水溶液和饱和食盐水洗涤,收集有机层并将其浓缩,残留物经柱层析纯化(二氯甲烷:甲醇=50:1),得到560 mg黄棕色油状产品,收率为83.71%。1H NMR (400 MHz, DMSO-d 6 ): δ12.13 (br, 3H), 7.83 (t, J = 5.3 Hz, 1H), 5.31 (s, 1H), 3.54–3.48 (m, 18H),3.24 (s, 8H), 3.26–3.23 (m, 2H), 3.11–3.07 (m, 1H), 2.40 (t, J = 6.2 Hz, 8H),2.32 (s, 1H), 2.08–2.03 (m, 1H), 1.97–1.77 (m, 6H), 1.57–1.44 (m, 6H), 1.38–1.31 (m, 6H), 1.16–1.04 (m, 8H), 0.94 (s, 3H), 0.89 (d, J = 6.5 Hz, 3H), 0.84(d, J = 6.5 Hz, 6H), 0.65 (s, 3H)。
实施例16
化合物22的制备
氩气环境下,将化合物21(117 mg, 0.13 mmol)溶于10 mL二氯甲烷中,于冰浴下依次加入N, N-二异丙基乙胺(198 μL, 1.17 mmol)、HATU(411 mg, 337 mg, 0.88 mmol)、1-羟基苯并三唑(96 mg, 0.70 mmol),将反应液继续置于0 ℃活化1 h。将化合物11(438mg, 0.57 mmol)溶于5 mL二氯甲烷中,待上述活化液反应1 h后,将该反应液滴加入活化液中,室温反应过夜。TLC监测反应完全后,减压旋除溶剂。残留物重新用乙酸乙酯溶解,用1NHCl水溶液和饱和食盐水洗涤,收集有机层并将其浓缩,残留物经柱层析纯化(二氯甲烷:甲醇=10:1),得到260 mg黄棕色油状产品,收率为64.68%。1H NMR (600 MHz, DMSO-d 6 ): δ8.50 (s, 2H), 8.36 (d, J = 7.8 Hz, 3H), 8.23 (s, 3H), 8.01 (d, J = 7.1 Hz,3H), 7.89 (s, 2H), 7.79 (s, 3H), 7.37–7.29 (m, 30H), 5.30 (s, 1H), 5.09 (s,6H), 5.06 (s, 6H), 4.76 (q, J = 6.8 Hz, 3H), 4.21–4.17 (m, 3H), 3.76–3.68 (m,6H), 3.49 (s, 18H), 3.20 (s, 8H), 3.13 (s, 9H), 3.03–2.99 (m, 6H), 2.92–2.87(m, 3H), 2.82–2.77 (m, 3H), 2.29–2.23 (m, 9H), 2.13–2.06 (m, 7H), 1.94–1.86(m, 2H), 1.83–1.75 (m, 3H), 1.56–1.42 (m, 25H), 1.36 (s, 10H), 1.19 (s, 42H),1.14–1.04 (m, 10H), 0.93 (s, 3H), 0.88 (d, J = 6.2 Hz, 3H), 0.83 (d, J = 6.2Hz, 6H), 0.63 (s, 3H)。
实施例17
配体I(3RGD-Chol)的制备
将化合物22(260 mg, 0.8 mmol)溶于10 mL甲醇中,加入钯炭(10% Pd/C , 100mg),在氢气环境(0.8 MPa)中于室温下反应72 h。反应完全后,滤除钯炭,滤液浓缩,用乙醚重结晶得123 mg白色固体,收率为60.29%。M.p. 190.6-191.3℃。1H NMR (400 MHz,CD3OD): δ 4.42–4.36 (m, 6H), 4.08–4.01 (m, 3H), 3.83–3.80 (m, 3H), 3.65–3.61(m, 18H), 3.57–3.54 (m, 3H), 3.40–3.37 (m, 4H), 3.34 (s, 6H), 3.18 (t, J =7.1 Hz, 8H), 2.90–2.83 (m, 3H), 2.58–2.53 (m, 3H), 2.44–2.37 (m, 9H), 2.32–2.25 (m, 7H), 2.06–1.94 (m, 5H), 1.90–1.79 (m, 7H), 1.78–1.65 (m, 11H), 1.65–1.57 (m, 10H), 1.57–1.48 (m, 10H), 1.32 (s, 44H), 1.24–1.08 (m, 10H), 0.93(d, J = 6.5 Hz, 3H), 0.88 (d, J = 6.5 Hz, 6H), 0.83 (s, 3H), 0.69 (s, 3H);HR-MS (ESI): m/z calculated for C122H216N22O32: 2501.59510, found: 2501.59116。
所述的脑胶质瘤靶向脂质体的具体制备方法
实施例18
脂质体的制备
薄膜-水化超声法作为经典的脂质体制备方法,应用最为广泛,操作简单,制备出的脂质体结构典型。因此,本申请选择采用薄膜-水化超声法来制备载紫杉醇脂质体。
根据对载紫杉醇脂质体的处方摸索,选取最优化处方:脂质材料摩尔比为胆固醇:大豆磷脂:配体=33:64:3,药脂质量比为脂质:紫杉醇=30:1,水化液为pH 7.4的磷酸盐缓冲液(PBS,0.11M)。我们用上述处方分别制备了6种载紫杉醇脂质体: 分别为PTX-Lip,PTX-1RGD-Lip,PTX-2RGD-Lip,PTX-3RGD-Lip,PTX-2×1RGD-Lip以及PTX-3×1RGD-Lip。
具体操作如下:称取处方量脂质材料和紫杉醇于50 mL茄形瓶中,依次将上述试剂溶于氯仿-甲醇(v : v = 1 : 1)的混合溶液。于37 ℃恒温水浴减压旋除溶剂,得到质地均匀的脂质薄膜,真空干燥过夜除去残余溶剂。向瓶中加入磷酸盐缓冲液(PBS, pH = 7.4),将茄形瓶置于37 ℃恒温空气浴摇床,180 rpm水化30 min后,冰浴下超声(80 W, 5 s, 5s)三分钟,即可得到均匀、略带乳光的脂质体溶液。
实施例19
脂质体的包封率及粒径与电位的测定
根据文献报道,本申请采用冷冻离心的方法将未包载的游离紫杉醇与载紫杉醇脂质体分离。按实施例 18所述方法分别制备PTX-Lip,PTX-1RGD-Lip,PTX-2RGD-Lip,PTX-3RGD-Lip,PTX-2×1RGD-Lip以及PTX-3×1RGD-Lip。取部分上述载紫杉醇脂质体溶液在4℃条件下,10000 rpm离心20 分钟,上清液即为不含游离紫杉醇的脂质体。分别取50 μL离心后的上清液和离心前的脂质体样品,加入450 μL甲醇,涡旋震摇10分钟使之完全破乳后,再次10000 rpm离心10分钟,取上清液注入高效液相色谱仪进行分析,并按公式计算载紫杉醇脂质体的包封率(encapsulation efficiency,EE%):EE% = A离心后/ A离心前× 100%,其中,A离心后和A离心前分别是指脂质体离心后和离心前的峰面积数值。此外,还对上述6种载紫杉醇脂质体进行了粒径和 Zeta电位的测定。将所制得的脂质体用超纯水稀释到适宜浓度后,采用激光粒度及Zeta电位分析仪测定脂质体的粒径及电位,各组脂质体的粒径、电位及包封率见表1。
表1:不同类型载紫杉醇脂质体的粒径、电位及包封率(mean ± SD, n = 3)
结果表明所有类型的载紫杉醇脂质体包封率良好,均在80%以上;粒径均在160 nm以下,分散性系数(polymer dispersity index,PDI)均在0.2左右,表明脂质体呈均匀分布;各组脂质体的ζ电位均在-20 mV以下,呈弱负电性。
实施例20
体外释药评价
通过透析法对不同配体修饰的脂质体的体外药物释放进行考察。取0.8 mL各组载紫杉醇脂质体或等浓度的游离药物紫杉醇(溶剂为乙醇:聚氧乙烯蓖麻油=1:1,v/v)分别置于8000-12000 Da的透析袋中,密封后置于40 mL透析介质(1% Tween 80的PBS溶液,v/v)中,于恒温摇床中缓慢震摇(37 ℃,45 rpm),于0 h、0.5 h、1 h、2 h、4 h、8 h、12 h、24 h、48 h分别取样0.1 mL,并加入等体积的释放介质,48 h后将透析袋中的液体与释放介质混匀并取样作为紫杉醇释放完全的样品。取出的样品按上述HPLC色谱条件进行分析。并计算各个时间点每个样品的累积释放度,绘制其释放行为曲线(n=3)。
结果表明,游离紫杉醇的释放较为迅速,孵育24 h释放达到80%以上,孵育48 h释放达90%以上。而其他各组载紫杉醇脂质体的释放均较为缓慢,48 h内释放65%左右,无明显突释现象。说明所制备的不同分枝RGD修饰的载紫杉醇脂质体具有改善药物释放的作用,可达到缓释的效果。且各组载紫杉醇脂质体的释放行为与不加修饰的脂质体无明显差异,说明将RGD修饰于脂质体表面不会影响其释药行为。
实施例21
血清稳定性评价
采用浊度法测定不同配体修饰的载紫杉醇脂质体在50%胎牛血清中的透光率,具体操作如下:取各组载紫杉醇脂质体分别与等体积的胎牛血清混合均匀,于37 ℃恒温摇床中缓慢震摇(45 rpm),于0 h、l h、2 h、4 h、8 h、12 h、24 h、48 h分别取样,通过酶标仪测定样品在750 nm处的吸光度值,并换算成透光率。
结果表明,所有脂质体在和胎牛血清共孵育48小时后,其透光率仍大于95%,无明显的聚集现象,表明所制备的脂质体具有较好的血清稳定性,为后期体外、体内等实验奠定了基础。
实施例22
溶血性评价
取18-22 g昆明小鼠,经眼眶取血置于涂有肝素钠的离心管中,于4 °C下离心(10000 rpm × 10 min),弃去上清液,并用PBS缓冲液清洗下层红细胞三次至上清液无色,最后用PBS缓冲液将红细胞重悬为2%(w/v)的溶液。按实施例18所述方法制备六种载紫杉醇脂质体,并用PBS缓冲液将其逐步稀释,使脂质浓度为400、200、100、50、25、10、5 nmol/mL。分别取上述不同浓度的脂质体0.2 mL与等体积的2%红细胞悬液混合后,于37 °C在恒温摇床中孵育1小时,10000 rpm离心10分钟,取上清液用酶标仪在波长540 nm处检测吸光度A。将1%曲拉通(聚乙二醇辛基苯基醚,Triton X-100)与红细胞共孵育的结果作为阳性对照,即溶血率为100%;以PBS与红细胞共同孵育的结果作为阴性对照,即溶血率为0%。各组脂质体的溶血率计算公式为:溶血率(percent hemolysis)% = (A样品-A阴性对照)/ (A阳性对照-A阴性对照)× 100%。
结果显示,在5 ~ 400 nmοΙ/mL脂质浓度范围内,6种脂质体均没有引起明显的血红蛋白的释放,溶血率均小于5%,有较好的生物安全性,可用于后期体内外活性评价。
实施例23
细胞摄取实验
按实施例18中载紫杉醇脂质体的制备方法,将紫杉醇替换为荧光剂CFPE,制备CFPE标记的脂质体。将C6细胞和bEnd.3细胞以3×105个/孔接种于12孔板中,将按上述6种CFPE标记的脂质体,用无血清培养基稀释后加入孔板中,使脂质浓度为0.3 μmol/mL,CFPE浓度为2 μg/mL,于细胞培养箱中孵育2 h。弃去含药培养基并用预冷PBS洗涤2次,消化收集细胞,于4 ℃下离心(2000 rpm × 3 min),弃去上清,用预冷PBS清洗2次后,将细胞用PBS重悬,用流式细胞仪检测细胞的荧光强度。
流式细胞仪的测试基础上,进一步采用激光共聚焦显微镜,对细胞摄取进行了更直观的研究,具体操作如下:将C6细胞和bEnd.3细胞分别以3×105个/孔的浓度接种于预置有盖玻片的6孔板中,于37 °C、5% CO2条件下培养24 h。弃去培养基,加入CFPE标记的六种脂质体1 mL/孔,使脂质浓度为0.3 μmol/mL,CFPE浓度为2 μg/mL,于细胞培养箱中孵育2 h后弃去含药培养基并用冰冷PBS洗涤2次,每次5 min,加入4%多聚甲醛固定30 min,弃去多聚甲醛,PBS清洗3次,每次5 min。加入5 μg/mL DAPI染料染核5 min,弃去染料, PBS清洗3次后,甘油封片,于激光共聚焦显微镜下拍摄。
C6细胞和bEnd.3细胞均对三分枝RGD修饰的脂质体3RGD-Lip表现出了最强的摄取能力。在C6细胞中,3RGD-Lip的荧光强度分别是Lip的3.61倍、1RGD-Lip的3.36倍、2RGD-Lip的2.26倍、2×1RGD-Lip的1.98倍和3×1RGD-Lip的1.84倍。bEnd.3细胞对3RGD-Lip的摄取分别是Lip的2.40倍、1RGD-Lip的1.44倍、2RGD-Lip的1.18倍、2×1RGD-Lip的1.17倍和3×1RGD-Lip的1.36倍。激光共聚焦的定性摄取实验结果表明,三分枝RGD修饰的脂质体3RGD-Lip 在αvβ3受体高表达的C6细胞和bEnd.3细胞内均显示出了最高的摄取水平,与流式细胞术的定量结果一致。
实施例24
摄取机制研究
将C6细胞和bEnd.3细胞分别以3×105个/孔接种于12孔板中,于 37 °C、5% CO2浓度中培养24 h后,弃去培养基,用PBS清洗一次后,分别加入含200 μg/mL RGD、10 μg/mL氯丙嘆、1 μg/mL菲律平、2 mg/mL盐酸阿米洛利以及1 mg/mL NaN3的无血清培养基,于37 ℃孵育30 min。弃去培养基,PBS清洗一次,将按实施例18所述方法制备的6种CFPE标记的脂质体,用无血清培养基稀释后加入孔板,使脂质浓度为0.3 μmol/mL,CFPE浓度为2 μg/mL,于细胞培养箱中孵育2 h。并设置低温组,即将加有脂质体的细胞于4 ℃条件下同样孵育2 h。弃去含药培养基并用预冷PBS洗涤2次,消化收集细胞,于4 ℃离心机中离心(2000 rpm ×3 min),弃去上清,用冰冷PBS清洗2次后,将细胞用PBS重 悬,用流式细胞仪检测细胞的荧光强度,计算各组相对正常摄取组(对照组)的摄取率。
由结果可知,C6细胞和bEnd.3细胞对3RGD-Lip的摄取是通过αvβ3受体介导、由多种内吞方式参与的、能量依赖的内吞方式实现的。
实施例25
细胞毒性实验
通过MTT法,考察不同配体修饰的载紫杉醇脂质体对鼠源脑胶质瘤细胞(C6)的毒性。
将C6细胞以5×103个/孔的浓度接种于96孔板内,在37 ℃、5% CO2的细胞培养箱内孵育24 h。按实施例18制备的六种载紫杉醇脂质体,用含10%胎牛血清(FBS)的培养基将载紫杉醇脂质体或游离紫杉醇逐步稀释为PTX浓度为10、5、2、1、0.5、0.2、0.1和0.01 μmol/L的溶液,加入细胞培养板内共同培养24 h。弃去培养基,向96孔板内依次加入200 μL MTT浓度为0.5 mg/mL的不含血清的培养基,于细胞培养箱中继续孵育4 h。弃去培养基,并向细胞孔内加入DMSO(150 μL),置于酶标仪中震荡均匀并于570 nm处测定其光密度吸收值OD。以不加药处理的细胞孔的OD值作为空白组,以不加细胞液并且不加药的培养基组的OD值作为背景组,计算给药组的细胞存活率公式为:存活率(cell viability)% =(OD样品-OD背景)/(OD空白-OD背景)× 100%。
结果显示,随着紫杉醇给药浓度的增加,PTX-Lip、PTX-1RGD-Lip、PTX-2RGD-Lip、PTX-3RGD-Lip、PTX-2×1RGD-Lip和PTX-3×1RGD-Lip对C6细胞的抑制能力逐渐增强。与其他类型的载紫杉醇脂质体相比,三分枝RGD修饰的脂质体PTX-3RGD-Lip对C6细胞均表现出最强的细胞毒性,在各个给药浓度下表现出最强的抑制脑胶质瘤细胞增殖的能力。
Claims (6)
2.根据权利要求1所述的三分枝RGD修饰的脑胶质瘤靶向脂质材料,其合成路线为:RGD部分,以Boc保护的甘氨酸、苄基保护的天冬氨酸以及Boc和硝基共同保护的精氨酸为原料,首先合成全保护的RGD三肽,然后脱除精氨酸的Boc保护基并用Boc保护的12-氨基十二酸进行延伸;胆甾部分,以胆固醇为起始原料,首先用三甘醇进行延伸,将三甘醇末端羟基改性为氨基,再与中间连接基团季戊四醇衍生物偶联,脱去RGD部分的Boc保护基后即可与三分子RGD肽偶联,最后脱去所有保护基即得。
3.权利要求1所述的三分枝RGD修饰的脑胶质瘤靶向脂质材料作为药物载体在制备脑胶质瘤靶向药物中的应用。
4.一种权利要求1所述的三分枝RGD修饰的脑胶质瘤靶向脂质材料所制成的脑胶质瘤靶向脂质体,其特征在于,包括膜材与活性剂;所述的膜材为磷脂双分子层,由卵磷脂、胆固醇以及权利要求1所述的脑胶质瘤靶向脂质材料组成,其中,各组分配比关系如下:胆固醇和卵磷脂的摩尔比为1~2:1~10,脑胶质瘤靶向脂质材料的摩尔含量为胆固醇和卵磷脂的总摩尔数的1~25%;活性剂为治疗剂或显影剂,活性剂的剂量按重量百分数计算,活性剂占总脂质的0.1%~50%;水化液为pH 7.4的0.01M磷酸盐缓冲液。
5.根据权利要求4所述的脑胶质瘤靶向脂质体,其特征在于,根据上述组分配比关系,采用薄膜法制备脑胶质瘤靶向脂质体,制备得到粒径及Zeta电位稳定的脑胶质瘤靶向脂质体,其脂质体粒度为160 nm以下,包封率大于80%。
6.根据权利要求4所述的脑胶质瘤靶向脂质体,其特征在于,所述活性剂为紫杉醇,显影剂为CFPE或DiD。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110757554.6A CN113577303B (zh) | 2021-07-05 | 2021-07-05 | 三分枝rgd修饰的脑胶质瘤靶向脂质材料的制备和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110757554.6A CN113577303B (zh) | 2021-07-05 | 2021-07-05 | 三分枝rgd修饰的脑胶质瘤靶向脂质材料的制备和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113577303A CN113577303A (zh) | 2021-11-02 |
CN113577303B true CN113577303B (zh) | 2023-06-02 |
Family
ID=78245849
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110757554.6A Active CN113577303B (zh) | 2021-07-05 | 2021-07-05 | 三分枝rgd修饰的脑胶质瘤靶向脂质材料的制备和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113577303B (zh) |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102266288A (zh) * | 2011-07-14 | 2011-12-07 | 四川大学 | 一种基于胆固醇修饰的还原敏感性肿瘤靶向脂质体 |
CN102532262A (zh) * | 2012-03-02 | 2012-07-04 | 首都医科大学 | 脂肪酸-rgd-脂肪醇偶联物介导表阿霉素靶向脂质体制备及抗肿瘤活性评价 |
CN105641711A (zh) * | 2016-01-25 | 2016-06-08 | 四川大学 | 以有机胺修饰的维生素c为载体的双重脑靶向前药 |
CN105693807A (zh) * | 2016-01-25 | 2016-06-22 | 四川大学 | 新型脑靶向脂质材料及其在药物传递系统中的应用 |
CN106310220A (zh) * | 2016-08-17 | 2017-01-11 | 浙江中医药大学 | 一种包封鳖甲肽的rgd‑ssl脂质体及其制备方法 |
CN108743953A (zh) * | 2018-06-13 | 2018-11-06 | 四川大学 | 一种新型双重脑肿瘤靶向脂质材料及其应用 |
CN109364026A (zh) * | 2018-11-26 | 2019-02-22 | 四川大学 | 生物素修饰的乳腺癌靶向脂质材料的制备和应用 |
CN110054660A (zh) * | 2018-12-25 | 2019-07-26 | 四川大学 | 一种果糖修饰的乳腺癌靶向脂质材料的制备和应用 |
CN110522923A (zh) * | 2019-09-19 | 2019-12-03 | 四川大学 | 果糖和rgd肽共修饰的双重靶向三阴性乳腺癌的脂质材料 |
CN110917139A (zh) * | 2019-12-02 | 2020-03-27 | 四川大学 | 多分枝生物素修饰的乳腺癌靶向脂质体的制备和应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040034336A1 (en) * | 2002-08-08 | 2004-02-19 | Neal Scott | Charged liposomes/micelles with encapsulted medical compounds |
AU2013243955B2 (en) * | 2012-04-02 | 2018-02-22 | Modernatx, Inc. | Modified polynucleotides for the production of oncology-related proteins and peptides |
-
2021
- 2021-07-05 CN CN202110757554.6A patent/CN113577303B/zh active Active
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102266288A (zh) * | 2011-07-14 | 2011-12-07 | 四川大学 | 一种基于胆固醇修饰的还原敏感性肿瘤靶向脂质体 |
CN102532262A (zh) * | 2012-03-02 | 2012-07-04 | 首都医科大学 | 脂肪酸-rgd-脂肪醇偶联物介导表阿霉素靶向脂质体制备及抗肿瘤活性评价 |
CN105641711A (zh) * | 2016-01-25 | 2016-06-08 | 四川大学 | 以有机胺修饰的维生素c为载体的双重脑靶向前药 |
CN105693807A (zh) * | 2016-01-25 | 2016-06-22 | 四川大学 | 新型脑靶向脂质材料及其在药物传递系统中的应用 |
CN106310220A (zh) * | 2016-08-17 | 2017-01-11 | 浙江中医药大学 | 一种包封鳖甲肽的rgd‑ssl脂质体及其制备方法 |
CN108743953A (zh) * | 2018-06-13 | 2018-11-06 | 四川大学 | 一种新型双重脑肿瘤靶向脂质材料及其应用 |
CN109364026A (zh) * | 2018-11-26 | 2019-02-22 | 四川大学 | 生物素修饰的乳腺癌靶向脂质材料的制备和应用 |
CN110054660A (zh) * | 2018-12-25 | 2019-07-26 | 四川大学 | 一种果糖修饰的乳腺癌靶向脂质材料的制备和应用 |
CN110522923A (zh) * | 2019-09-19 | 2019-12-03 | 四川大学 | 果糖和rgd肽共修饰的双重靶向三阴性乳腺癌的脂质材料 |
CN110917139A (zh) * | 2019-12-02 | 2020-03-27 | 四川大学 | 多分枝生物素修饰的乳腺癌靶向脂质体的制备和应用 |
Non-Patent Citations (5)
Title |
---|
Englund EA等.Programmable multivalent display of receptor ligands using peptide nucleic acid nanoscaffolds.《Nat Commun》.2012,第20卷(第12期),第614页. * |
Guo Z等.Targeting efficiency of RGD-modified nanocarriers with different ligand intervals in response to integrin αvβ3 clustering.《Biomaterials》.2014,第35卷(第23期),第6106–6117页. * |
Zhiyang Li等.Triple branched RGD modification on liposomes: A prospective strategy to enhance the glioma targeting efficiency.《Bioorganic & Medicinal Chemistry》.2022,第60卷第1-16页. * |
左甜甜.RGD介导多西他赛pH敏感脂质体的合成、制备、表征及体内外抗肿瘤活性评价.《山东大学硕士学位论文》.2015,全文. * |
魏霖.RGD肽与可剪切PEG共修饰脂质体的构建及体外抗肿瘤作用评价.《苏州大学硕士学位论文》.2013,全文. * |
Also Published As
Publication number | Publication date |
---|---|
CN113577303A (zh) | 2021-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11413281B2 (en) | Ternary conjugate of antitumor drug, and synthesis and application | |
EP0636028B1 (en) | Self-assembling polynucleotide delivery system comprising an amphiphatic cationic peptide | |
Chandran et al. | Characterization of a targeted nanoparticle functionalized with a urea-based inhibitor of prostate-specific membrane antigen (PSMA) | |
KR102190093B1 (ko) | 난소암을 특이적으로 표적하는 생분해성 양친성 폴리머, 이로부터 제조된 폴리머 배시클 및 용도 | |
Pu et al. | Dual-targeting liposomes with active recognition of GLUT5 and αvβ3 for triple-negative breast cancer | |
JP5271912B2 (ja) | 標的化リガンドを固定化するための改良型リンカー | |
CN112274656B (zh) | 可将组合药物按比例递送至肿瘤组织的大环两亲自组装纳米颗粒的制备方法和应用 | |
CN107286222B (zh) | 一种靶向肿瘤干细胞标志物cd133的多肽及其应用 | |
BR112014032919B1 (pt) | Conjugado e seu método de produção, lipossomas, uso e método de produção dos mesmos, bem como composição farmacêutica | |
CN108164584B (zh) | Vap多肽及其在制备靶向诊疗肿瘤药物中的应用 | |
CN107496937B (zh) | 一种预靶向给药体系及其制备方法和应用 | |
CN107266384B (zh) | 基于2-氨基十六烷酸的n-羧基内酸酐单体和聚氨基酸及其制备方法 | |
CN109432049B (zh) | 一种具有肾脏靶向分布特性的大黄酸脂质囊纳米粒及应用 | |
CN109422801B (zh) | 多功能靶向多肽rap及其在制备肿瘤靶向递送系统中的用途 | |
CN110840844A (zh) | 生物素与葡萄糖共同修饰的乳腺癌靶向脂质体的制备和应用 | |
CN110917139A (zh) | 多分枝生物素修饰的乳腺癌靶向脂质体的制备和应用 | |
CN113577303B (zh) | 三分枝rgd修饰的脑胶质瘤靶向脂质材料的制备和应用 | |
CN110522923A (zh) | 果糖和rgd肽共修饰的双重靶向三阴性乳腺癌的脂质材料 | |
CN111001006A (zh) | 葫芦素b和氧化响应抗肿瘤前药共载仿生纳米粒 | |
KR100773029B1 (ko) | 수용성 미셀을 형성하는 생분해성 고리형 삼합체 포스파젠-탁솔 컨쥬게이트 항암제 및 이의 제조방법 | |
CN103319710A (zh) | 聚(2-乙基-2-恶唑啉)-脂质衍生物及制备方法 | |
CN113546179B (zh) | 一种阿霉素长循环脂质体靶向药物及其制备方法 | |
CN113398276B (zh) | 脑胶质瘤靶向小檗碱与叶酸修饰的脂质材料的制备与应用 | |
JPWO2019208820A1 (ja) | 細胞内物質移送システムおよびその利用 | |
CN111166892A (zh) | 生物素和穿膜肽共同介导的乳腺癌靶向智能脂质体材料 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |